AIM ImmunoTech: Difference between revisions
Joe Bacchus (talk | contribs) No edit summary |
Joe Bacchus (talk | contribs) No edit summary |
||
| Line 70: | Line 70: | ||
In June, 2018, Hemispherx announced that Ampligen had shown effectiveness in activating the [[TLR3]] without triggering T-cell regulatory activities, offering a potentially effective way to treat tumors.<ref>{{cite web|title=Hemispherx Biopharma (HEB) Highlights New Data Showing Ampligen’s Positive Role in Reprograming Tumor Microenvironment|url=https://www.streetinsider.com/FDA/Hemispherx+Biopharma+%28HEB%29+Highlights+New+Data+Showing+Ampligen%E2%80%99s+Positive+Role+in+Reprograming+Tumor+Microenvironment/14274191.html|publisher=Street Insider|date=5 June 2018}}</ref> |
In June, 2018, Hemispherx announced that Ampligen had shown effectiveness in activating the [[TLR3]] without triggering T-cell regulatory activities, offering a potentially effective way to treat tumors.<ref>{{cite web|title=Hemispherx Biopharma (HEB) Highlights New Data Showing Ampligen’s Positive Role in Reprograming Tumor Microenvironment|url=https://www.streetinsider.com/FDA/Hemispherx+Biopharma+%28HEB%29+Highlights+New+Data+Showing+Ampligen%E2%80%99s+Positive+Role+in+Reprograming+Tumor+Microenvironment/14274191.html|publisher=Street Insider|date=5 June 2018}}</ref> |
||
As of June |
As of June 2019, Hemispherx is operating 5 studies examining the viability of Ampligen for combating [[Ovarian cancer]], to which end it has also raised tens of millions of dollars in shareholder capital.<ref>[https://hemispherx.irpass.com/Hemispherx-Reports-2019-First-Quarter-Financial-Results Hemispherx Reports 2019 First Quarter Financial Results]</ref> |
||
On September 3, 2019, Hemispherx Biopharma was renamed to AIM Immunotech.<ref>{{cite news |date=2019-08-23 |title=Brief-Hemispherx Biopharma Inc Changes Name To Aim Immunotech Inc |url=https://www.msn.com/en-us/money/news/brief-hemispherx-biopharma-inc-changes-name-to-aim-immunotech-inc/ar-AAGdX2P |agency=[[Reuters]] |via=[[MSN]] |accessdate=2020-01-23 |archiveurl=https://web.archive.org/web/20200123083013/https://www.msn.com/en-us/money/news/brief-hemispherx-biopharma-inc-changes-name-to-aim-immunotech-inc/ar-AAGdX2P |archivedate=2020-01-23 }}</ref> |
On September 3, 2019, Hemispherx Biopharma was renamed to AIM Immunotech.<ref>{{cite news |date=2019-08-23 |title=Brief-Hemispherx Biopharma Inc Changes Name To Aim Immunotech Inc |url=https://www.msn.com/en-us/money/news/brief-hemispherx-biopharma-inc-changes-name-to-aim-immunotech-inc/ar-AAGdX2P |agency=[[Reuters]] |via=[[MSN]] |accessdate=2020-01-23 |archiveurl=https://web.archive.org/web/20200123083013/https://www.msn.com/en-us/money/news/brief-hemispherx-biopharma-inc-changes-name-to-aim-immunotech-inc/ar-AAGdX2P |archivedate=2020-01-23 }}</ref> |
||
Revision as of 16:27, 23 January 2020
 AIM ImmunoTech company logo. | |
| AIM | |
| AMEX: AIM | |
| Industry | Biopharmaceutical |
| Headquarters | , |
Key people | CEO Thomas K. Equels, M.S. J.D. CMO David R. Strayer, M.D. |
| Products | Ampligen® Alferon® |
| Services | Cancer research |
| Total assets | $ 15.965 million  (2019[1]) |
AIM ImmunoTech Inc. (AMEX: AIM), formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida.[2] Founded in 1990, the company has 32 employees.[3]
History
The company has created an immunomodulatory double stranded RNA drug called Ampligen.[4] The company is developing Ampligen to use as a treatment for multiple cancer tumor types and for chronic fatigue syndrome.[5]
On April 3, 2001, Hemispherx Biopharma, Inc. adjusted and restated its 1999 financial statements to reflect charges relating to an extension of the exercise period to certain warrants as of February 1999.
On April 3, 2006, Hemispherx Biopharma, Inc. restated financial results for 2003 and 2004 due to accounting mistakes related to debentures and warrants issued between March 2003 and August 2005.[6]
In June, 2018, Hemispherx announced that Ampligen had shown effectiveness in activating the TLR3 without triggering T-cell regulatory activities, offering a potentially effective way to treat tumors.[7]
As of June 2019, Hemispherx is operating 5 studies examining the viability of Ampligen for combating Ovarian cancer, to which end it has also raised tens of millions of dollars in shareholder capital.[8]
On September 3, 2019, Hemispherx Biopharma was renamed to AIM Immunotech.[9]
References
- ^ SEC Filings
- ^ Greenberg, Herb (1998-09-18). "Battle Royale Brewing: Hemispherx Biopharma and Asensio Tangle". TheStreet.com. Archived from the original on 24 August 2009. Retrieved 24 August 2009.
- ^ "Hemispherx Biopharma, Inc". BusinessWeek. Archived from the original on 24 August 2009. Retrieved 24 August 2009.
- ^ "Hemispherx licensed for chemical compound". Philadelphia Business Journal. 2006-08-29. Archived from the original on 24 August 2009. Retrieved 24 August 2009.
- ^ "Hemispherx Biopharma Inc. (use of Ampligen for chronic fatigue syndrome)". Philadelphia Business Journal. 2000-10-06. Retrieved 24 August 2009.
- ^ "Hemispherx delays 2005 statement".
- ^ "Hemispherx Biopharma (HEB) Highlights New Data Showing Ampligen's Positive Role in Reprograming Tumor Microenvironment". Street Insider. 5 June 2018.
- ^ Hemispherx Reports 2019 First Quarter Financial Results
- ^ "Brief-Hemispherx Biopharma Inc Changes Name To Aim Immunotech Inc". Reuters. 2019-08-23. Archived from the original on 2020-01-23. Retrieved 2020-01-23 – via MSN.